Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer: current and emerging applications
Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) is transforming the management of patients with prostate cancer. In appropriately selected patients, PSMA-PET offers superior sensitivity and specificity compared to conventional imaging (e.g., computed tomography and bone scintigraphy) as well as choline and fluciclovine PET, with the added benefit of consolidating bone and soft tissue evaluation into a single study. Despite being a newly available imaging tool, PSMA-PET has established indications, interpretation guidelines, and reporting criteria, which will be reviewed. The prostate cancer care team, from imaging specialists to those delivering treatment, should have knowledge of physiologic PSMA radiotracer uptake, patterns of disease spread, and the strengths and limitations of PSMA-PET. In this review, current and emerging applications of PSMA-PET, including appropriateness use criteria as well as image interpretation and pitfalls, will be provided with an emphasis on clinical implications. Graphical abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Abdominal radiology - 49(2024), 4 vom: 22. Feb., Seite 1288-1305 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Moran, Shamus [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00261-024-04188-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055220320 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055220320 | ||
| 003 | DE-627 | ||
| 005 | 20240321064644.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240321s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00261-024-04188-w |2 doi | |
| 035 | |a (DE-627)SPR055220320 | ||
| 035 | |a (SPR)s00261-024-04188-w-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Moran, Shamus |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer: current and emerging applications |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) is transforming the management of patients with prostate cancer. In appropriately selected patients, PSMA-PET offers superior sensitivity and specificity compared to conventional imaging (e.g., computed tomography and bone scintigraphy) as well as choline and fluciclovine PET, with the added benefit of consolidating bone and soft tissue evaluation into a single study. Despite being a newly available imaging tool, PSMA-PET has established indications, interpretation guidelines, and reporting criteria, which will be reviewed. The prostate cancer care team, from imaging specialists to those delivering treatment, should have knowledge of physiologic PSMA radiotracer uptake, patterns of disease spread, and the strengths and limitations of PSMA-PET. In this review, current and emerging applications of PSMA-PET, including appropriateness use criteria as well as image interpretation and pitfalls, will be provided with an emphasis on clinical implications. Graphical abstract | ||
| 650 | 4 | |a PSMA |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a PET/CT |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Prostate cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Imaging |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Cheng, Heather H. |4 aut | |
| 700 | 1 | |a Weg, Emily |4 aut | |
| 700 | 1 | |a Kim, Eric H. |4 aut | |
| 700 | 1 | |a Chen, Delphine L. |4 aut | |
| 700 | 1 | |a Iravani, Amir |4 aut | |
| 700 | 1 | |a Ippolito, Joseph E. |0 (orcid)0000-0003-1913-5573 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Abdominal radiology |d Springer US, 2016 |g 49(2024), 4 vom: 22. Feb., Seite 1288-1305 |w (DE-627)SPR003173186 |w (DE-600)2845742-0 |x 2366-0058 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2024 |g number:4 |g day:22 |g month:02 |g pages:1288-1305 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00261-024-04188-w |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2024 |e 4 |b 22 |c 02 |h 1288-1305 | ||